Clinical Trial Update: Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bempegaldesleukin (NKTR-214) with radiation and anti-PD-1 for head and neck squamous cell carcinoma was terminated; results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Anti-PD-1
• Bempegaldesleukin (bempegaldesleukin)
• Radiation therapy

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Head and Neck Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-04-04